CT1812 slows cognitive decline in proof-of-concept Alzheimer's trial
CT1812 was shown to slow the decline of cognitive function in adults with Alzheimer’s disease in a proof-of-concept clinical trial.| Alzheimer's News Today
CT1812 was shown to slow the decline of cognitive function in adults with Alzheimer’s disease in a proof-of-concept clinical trial.| Alzheimer's News Today
